Idelalisib (GS-1101/CAL-101) is a selective inhibitor of the p110d isoform of PI3K, an enzyme downstream of the BCR responsible for transduction of pro-survival signals in CLL[190]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.